WO2022214023A1 - 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 - Google Patents
基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 Download PDFInfo
- Publication number
- WO2022214023A1 WO2022214023A1 PCT/CN2022/085517 CN2022085517W WO2022214023A1 WO 2022214023 A1 WO2022214023 A1 WO 2022214023A1 CN 2022085517 W CN2022085517 W CN 2022085517W WO 2022214023 A1 WO2022214023 A1 WO 2022214023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- screening
- protein
- fusion protein
- cells
- suicide
- Prior art date
Links
- 238000012216 screening Methods 0.000 title claims abstract description 81
- 239000005557 antagonist Substances 0.000 title abstract description 5
- 239000003596 drug target Substances 0.000 title abstract description 4
- 230000034994 death Effects 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 133
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 106
- 206010010144 Completed suicide Diseases 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims description 163
- 102000037865 fusion proteins Human genes 0.000 claims description 85
- 108020001507 fusion proteins Proteins 0.000 claims description 85
- 230000006907 apoptotic process Effects 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 43
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 41
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 37
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 36
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 claims description 22
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 claims description 22
- -1 small molecule compounds Chemical class 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 239000000411 inducer Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 15
- 101150105104 Kras gene Proteins 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 229940000406 drug candidate Drugs 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 229940125415 protein degrader Drugs 0.000 claims description 11
- 101800000509 Non-structural protein 8 Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 7
- 102000017578 LAG3 Human genes 0.000 claims description 7
- 108060000903 Beta-catenin Proteins 0.000 claims description 6
- 102000015735 Beta-catenin Human genes 0.000 claims description 6
- 102100035904 Caspase-1 Human genes 0.000 claims description 6
- 108090000426 Caspase-1 Proteins 0.000 claims description 6
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 claims description 6
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims description 6
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000012106 screening analysis Methods 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 102100021158 Double homeobox protein 4 Human genes 0.000 claims description 4
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 claims description 4
- 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 claims description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 4
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 claims description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 4
- 101800000510 Non-structural protein 7 Proteins 0.000 claims description 4
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 4
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 4
- 108091006269 SLC5A2 Proteins 0.000 claims description 4
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 3
- 101150039798 MYC gene Proteins 0.000 claims description 3
- 101000867820 Rattus norvegicus Voltage-dependent L-type calcium channel subunit alpha-1D Proteins 0.000 claims description 3
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000013480 data collection Methods 0.000 claims 2
- 238000013537 high throughput screening Methods 0.000 abstract description 16
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 abstract description 9
- 102200015453 rs121912293 Human genes 0.000 abstract description 9
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 238000006731 degradation reaction Methods 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 229940121649 protein inhibitor Drugs 0.000 abstract description 3
- 239000012268 protein inhibitor Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 28
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- GQLCLPLEEOUJQC-ZTQDTCGGSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyph Chemical group C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCC(=O)NCCNC(=O)COC=2C=C(C=CC=2)[C@@H](CCC=2C=C(OC)C(OC)=CC=2)OC(=O)[C@H]2N(CCCC2)C(=O)[C@@H](CC)C=2C=C(OC)C(OC)=C(OC)C=2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 GQLCLPLEEOUJQC-ZTQDTCGGSA-N 0.000 description 21
- 108091033319 polynucleotide Proteins 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108090000566 Caspase-9 Proteins 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 102000004039 Caspase-9 Human genes 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 239000001064 degrader Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 7
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000017854 proteolysis Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000012743 protein tagging Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 2
- 101001027052 Homo sapiens Thymidylate kinase Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 1
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710118186 Neomycin resistance protein Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006212 diphosphorylation reaction Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 102000038037 druggable proteins Human genes 0.000 description 1
- 108091007999 druggable proteins Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009873 pyroptotic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229950004008 rimiducid Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108700010449 tumor-promoting protein Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- a live detection cell expresses an exogenous fusion protein
- the fusion protein is a fusion protein of a target protein and a cell suicide element, wherein the fusion protein induces all the proteins in the presence of a suicide inducer.
- the suicide inducer does not induce the detection cell to undergo apoptosis.
- the drug candidate is selected from the group consisting of a protein degrader of a target protein, a transcription inhibitor of the target protein, or a combination thereof.
- the target protein is a disease target protein.
- test substance to be screened is selected from small molecule compounds, nucleic acid molecules, and proteasome targeting chimeras (PROTAC).
- the structure of the cell suicide element is shown in the following formula II:
- C is a suicide gene element.
- the F is the FKBP12-F36V domain.
- amino acid sequence of the suicide gene element is shown in SEQ ID NO: 1.
- the method further comprises: (c2) testing the degradation effect of the drug candidate on the target protein, the inhibitory effect on the transcription of the target protein, and/or the preventive or therapeutic effect on the disease related to the target protein .
- an apoptosis screening module includes one or more culture units, and the culture unit is provided with n culture chambers (or wells) (compartments) for culturing live detection cells, wherein the culture chamber contains the screening system for screening inhibitors against the target protein according to the first aspect of the present invention; n is a positive integer ⁇ 2;
- the number of the culture units is 1-200, preferably 4-100, more preferably 8-50, and most preferably 10-20.
- a fusion protein is provided, and the structure of the fusion protein is shown in formula I:
- the disease target is selected from the group consisting of: tumor-promoting protein target, tumor immune target, diabetes target, neurodegenerative disease target, novel coronavirus target, genetic disease target, or its combination.
- the disease target protein is selected from the following group: PD-1, PD-L1, CD47, LAG3, TIGIT, KRas, Myc, TERT, SKP2, AR, PAX3, DUX4, SGLT2, SNCA, RdRp , NSP7, NSP8, RBD, IMPDH1, RANK, ⁇ -Catenin, FLI1, Caspase1, Spike, NSP8.
- L2 is no or flexible joint
- the F is the FKBP12-F36V domain.
- the FKBP12-F36V domain comprises a FKBP domain, and the 36th amino acid of the FKBP domain is mutated from phenylalanine to valine.
- nucleic acid molecule encoding the fusion protein according to the fifth aspect of the present invention.
- a vector containing the nucleic acid molecule according to the sixth aspect of the present invention there is provided a vector containing the nucleic acid molecule according to the sixth aspect of the present invention.
- novel screening system of the present invention screening system for protein degraders of the present invention
- drug screening system based on conditional suicide protein (F-C fusion protein) can be used interchangeably, and all refer to the present invention.
- the screening system for screening an inhibitor against a target protein according to the first aspect.
- the sequence of the target protein PD1 is:
- novel screening system of the present invention can be applied to the screening of antagonists of various disease target proteins
- PD1 was fused to F-C protein and expressed in cells.
- the artificially synthesized small molecule compound A6 was screened through the screening process in Figure 4. After the cells expressing PD1-F-C fusion protein were treated with DMSO or A6 for 24 h, and AP1903 was added, the cells in the DMSO control group died, but after compound A6 was added, the cells no longer died, suggesting that A6 has an antagonistic effect on PD1 gene.
- Jurkat cells were activated by PMA and inonmycin, and treated with A6 at the same time.
- the PD1 mRNA expression level was detected by qPCR, and the PD1 mRNA level was significantly decreased in the cells treated with A6.
- the experimental results showed that A6 treatment was added while activating Jurkat T cells. It can be seen by FACS and qPCR that compared with the control group, the A6-treated Jurkat T cells had no expression of PD1 on the membrane surface, and the expression of PD1 mRNA in the cells. The amount is also lower.
- Jurkat cells overexpressing exogenous HA-PD1 were treated with A6, and the level of PD1 was detected by Western Blot, and the level of PD1 protein in cells treated with A6 was decreased.
- the inventors also tested in Jurkat T cells stably expressing exogenous HA tag-PD1. Western Blot results showed that Jurkat-HA-PD1 cells treated with A6 had lower PD1 stability.
- the inventors constructed a simple and efficient experimental system for screening target gene transcription inhibitors and protein degraders by using the fusion of F-C protein and drug target protein.
- Example 3 High-throughput screening of the protein degrader screening system of the present invention
- LAG3 a target for tumor immunotherapy. As a co-inhibitory receptor, LAG3 regulates immune homeostasis, T cell activation and function, and cytokine production by transmitting immunosuppressive signals. important role.
- Spike and NSP8 Targets for the novel coronavirus.
- SARS-CoV-2 enters cells by binding to the human cell surface receptor ACE2 through Spike;
- NSP8 is very important for RNA replication of the coronavirus family, and its structure is damaged, which will seriously affect viral RNA synthesis.
- the target protein and green fluorescent protein GFP are formed into a fusion protein, and the transcription inhibitor or protein degrader of the target protein is screened according to the change of the fluorescence intensity of GFP.
- the phenotype mediated by the conditional suicide protein FKBP12(F36V)-Caspase9 of the present invention is a highly sensitive and stable experimental phenotype, and a reduction of 75% can produce a very clear phenotype. Changes in live and dead phenotypes.
- the screened PD1 transcription inhibitor compound A6 can clearly change the dead-live phenotype under the PD1-F-C fusion system.
- Fig. 7c in the PD1-GFP fusion protein system, treated with the same experimental conditions, the change of the GFP fluorescence value was imperceptible by the treatment of compound A6.
- HPRT after HPRT activates 6TG, it undergoes monophosphorylation, diphosphorylation, triphosphorylation, ribose deoxygenation, incorporation into DNA, recognition by clip mismatch mechanisms, DNA damage, double-strand breaks, p53 activation, PUMA expression, mitochondrial
- caspase 9 can be activated to kill cells. All of these processes may be interfered with by compounds, resulting in cell survival phenotypes independent of target protein expression levels, resulting in false-positive results in high-throughput screening.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
最初的残基 | 代表性的取代 | 优选的取代 |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
Claims (16)
- 一种用于筛选针对靶标蛋白的抑制剂的筛选体系,其特征在于,所述筛选体系包括一培养体系以及存在于所述培养体系中的以下组分:(a)活的检测细胞,所述检测细胞表达外源的融合蛋白,所述的融合蛋白为靶标蛋白和细胞自杀元件的融合蛋白,其中,所述融合蛋白在自杀诱导剂存在下会诱导所述检测细胞发生凋亡;(b)待筛选的测试物;其中,当所述检测细胞表达所述的融合蛋白且所述的测试物不导致所述融合蛋白降解或减少时,所述自杀诱导剂会诱导所述检测细胞发生凋亡;并且,所述测试物导致所述检测细胞不表达所述的融合蛋白或导致所述融合蛋白降解或减少时,则所述自杀诱导剂不诱导所述检测细胞发生凋亡。
- 如权利要求1所述的筛选体系,其特征在于,所述筛选体系还包括:(c)自杀诱导剂,所述自杀诱导剂通过所述的融合蛋白诱导所述检测细胞凋亡。
- 如权利要求1所述的筛选体系,其特征在于,所述待筛选的测试物为所述靶标蛋白的蛋白降解剂和/或转录抑制剂。
- 如权利要求3所述的筛选体系,其特征在于,所述待筛选的测试物选自小分子化合物、核酸分子、蛋白酶体靶向嵌合体(PROTAC)。
- 如权利要求1所述的筛选体系,其特征在于,所述靶标蛋白和细胞自杀元件的融合蛋白结构如式I所示:B-L1-A 式I式中,B为靶标蛋白,优选为疾病靶标蛋白;A为细胞自杀元件;L1为无或接头序列;“-”独立地为连接肽或肽键。
- 如权利要求1所述的筛选体系,其特征在于,所述疾病靶标蛋白选自下组:PD1、PD-L1、CD47、LAG3、TIGIT、KRas、Myc、TERT、SKP2、AR、PAX3、DUX4、SGLT2、 SNCA、RdRp、NSP7、NSP8、RBD、IMPDH1、RANK、β-Catenin、FLI1、Caspase1、刺突蛋白(Spike)、NSP8。
- 如权利要求5所述的筛选体系,其特征在于,所述的细胞自杀元件的结构如下式II所示:F-L2-C (II)其中,各“-”独立地为连接肽或肽键;F为自杀基因诱导元件;L2为无或柔性接头;C为自杀基因元件。
- 一种筛选针对靶标蛋白的候选药物的方法,其特征在于,包括步骤:(a)将加入待筛选的测试物的培养体系作为实验组;将不加入测试化合物的培养体系作为空白对照组,其中,所述的培养体系中含有培养的活的检测细胞,所述检测细胞表达外源的融合蛋白,所述的融合蛋白为所述靶标蛋白和细胞自杀元件的融合蛋白,其中,所述融合蛋白在自杀诱导剂存在下会诱导所述检测细胞发生凋亡;和(b)向所述实验组和空白对照组中加入自杀诱导剂,观测实验组和空白对照组中检测细胞的存活情况;其中,当实验组中检测细胞的存活数量显著高于对照组时,则表明该测试物为候选药物。
- 一种如权利要求1所述的筛选体系的用途,其特征在于,用于筛选靶标蛋白的蛋白降解剂和/或转录抑制剂。
- 一种用于筛选针对靶标蛋白的抑制剂的筛选装置,其特征在于,所述装置包括:(d1)凋亡筛选模块,所述的凋亡筛选模块包括一个或多个培养单元,所述培养单元中设有n个用于培养活的检测细胞的培养室(或孔)(compartment),其中在所述培养室中含有权利要求1所述的用于筛选针对靶标蛋白的抑制剂的筛选体系;n为≥2的正整数;(d2)数据采集模块,所述数据采集模块被配置为对凋亡筛选模块中各个培养室中的所述检测细胞的凋亡情况进行数据采集;(d3)筛选分析模块,所述筛选分析模块被配置为对来自所述数据采集模块的细胞凋亡情况进行分析,获得待筛选的测试物是否是针对靶标蛋白的抑制剂的分析结果;和(d4)输出模块,所述输出模块输出筛选分析模块的分析结果。
- 如权利要求10所述的筛选装置,其特征在于,所述培养单元的数量为1-200个,较佳地4-100个,更佳地8-50个,最佳地10-20个。
- 一种融合蛋白,其特征在于,所述融合蛋白的结构如式I所示:B-L1-A 式I式中,B为疾病靶标蛋白;A为细胞自杀元件;L1为无或接头序列;“-”独立地为连接肽或肽键。
- 如权利要求12所述的融合蛋白,其特征在于,所述的细胞自杀元件的结构如下式II所示:F-L2-C (II)其中,各“-”独立地为连接肽或肽键;F为自杀基因诱导元件;L2为无或柔性接头;C为自杀基因元件。
- 一种核酸分子,其特征在于,所述核酸分子编码如权利要求12所述的融合蛋白。
- 一种载体,其特征在于,所述载体含有如权利要求14所述的核酸分子。
- 一种宿主细胞,其特征在于,所述的宿主细胞含有如权利要求15所述的载体或染色体中整合有如权利要求14所述的核酸分子。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022253522A AU2022253522A1 (en) | 2021-04-09 | 2022-04-07 | Novel screening system for drug target antagonist based on cell life/death phenotype |
CA3215029A CA3215029A1 (en) | 2021-04-09 | 2022-04-07 | Novel screening system for drug target antagonist based on cell life/death phenotype |
EP22784089.9A EP4321624A1 (en) | 2021-04-09 | 2022-04-07 | Novel screening system for drug target antagonist based on cell life/death phenotype |
JP2023561631A JP2024513462A (ja) | 2021-04-09 | 2022-04-07 | 細胞生死表現型に基づく薬物標的アンタゴニストの新規スクリーニングシステム |
US18/554,490 US20240192197A1 (en) | 2021-04-09 | 2022-04-07 | Novel screening system for drug target antagonist based on cell life/death phenotype |
KR1020237038520A KR20230169231A (ko) | 2021-04-09 | 2022-04-07 | 세포 생존/사멸 표현형 기반의 약물 표적 길항제의 신규 스크리닝 시스템 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110385275.1 | 2021-04-09 | ||
CN202110385275.1A CN115197989A (zh) | 2021-04-09 | 2021-04-09 | 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022214023A1 true WO2022214023A1 (zh) | 2022-10-13 |
Family
ID=83545063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/085517 WO2022214023A1 (zh) | 2021-04-09 | 2022-04-07 | 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240192197A1 (zh) |
EP (1) | EP4321624A1 (zh) |
JP (1) | JP2024513462A (zh) |
KR (1) | KR20230169231A (zh) |
CN (1) | CN115197989A (zh) |
AU (1) | AU2022253522A1 (zh) |
CA (1) | CA3215029A1 (zh) |
WO (1) | WO2022214023A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789389A (zh) * | 2005-11-23 | 2014-05-14 | 杰勒德·M·豪斯 | 鉴定、合成、优化和表征蛋白调节剂的化合物和方法 |
US20160166613A1 (en) * | 2014-12-15 | 2016-06-16 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
CN108330140A (zh) * | 2017-01-19 | 2018-07-27 | 西南大学 | 一种免筛选原/真核双表达载体及其构建与应用 |
CN109593721A (zh) * | 2017-09-30 | 2019-04-09 | 亘喜生物科技(上海)有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
-
2021
- 2021-04-09 CN CN202110385275.1A patent/CN115197989A/zh active Pending
-
2022
- 2022-04-07 JP JP2023561631A patent/JP2024513462A/ja active Pending
- 2022-04-07 KR KR1020237038520A patent/KR20230169231A/ko active Search and Examination
- 2022-04-07 AU AU2022253522A patent/AU2022253522A1/en active Pending
- 2022-04-07 WO PCT/CN2022/085517 patent/WO2022214023A1/zh active Application Filing
- 2022-04-07 US US18/554,490 patent/US20240192197A1/en active Pending
- 2022-04-07 CA CA3215029A patent/CA3215029A1/en active Pending
- 2022-04-07 EP EP22784089.9A patent/EP4321624A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789389A (zh) * | 2005-11-23 | 2014-05-14 | 杰勒德·M·豪斯 | 鉴定、合成、优化和表征蛋白调节剂的化合物和方法 |
US20160166613A1 (en) * | 2014-12-15 | 2016-06-16 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
CN108330140A (zh) * | 2017-01-19 | 2018-07-27 | 西南大学 | 一种免筛选原/真核双表达载体及其构建与应用 |
CN109593721A (zh) * | 2017-09-30 | 2019-04-09 | 亘喜生物科技(上海)有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
Non-Patent Citations (6)
Title |
---|
ANTONIO DI STASI, SIOK-KEEN TEY, GIANPIETRO DOTTI, YURIKO FUJITA, ALANA KENNEDY-NASSER, CARIDAD MARTINEZ, KARIN STRAATHOF, ENLI L: "Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 365, 3 November 2011 (2011-11-03), US , pages 1673 - 1683, XP002756622, DOI: 10.1056/NEJMoa1106152 * |
BENJAMIN S. JONES, LAWRENCE S. LAMB, FREDERICK GOLDMAN, ANTONIO DI STASI: "Improving the safety of cell therapy products by suicide gene transfer", FRONTIERS IN PHARMACOLOGY, vol. 5, XP055340558, DOI: 10.3389/fphar.2014.00254 * |
J.BIOL.CHEM, vol. 243, 1968, pages 3558 |
SAMBROOKRUSSELL ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, CSHL PRESS |
SHI ZHONG-DONG, JASON TCHAO, LING WU, AARON J. CARMAN: "Precision installation of a highly efficient suicide gene safety switch in human induced pluripotent stem cells", STEM CELLS TRANSLATIONAL MEDICINE, vol. 9, 13 July 2020 (2020-07-13), pages 1378 - 1388, XP055975373, DOI: 10.1002/sctm.20-0007 * |
TEY, S.K. DOTTI, G. ROONEY, C.M. HESLOP, H.E. BRENNER, M.K.: "Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 13, no. 8, 18 July 2007 (2007-07-18), US , pages 913 - 924, XP022157037, ISSN: 1083-8791, DOI: 10.1016/j.bbmt.2007.04.005 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230169231A (ko) | 2023-12-15 |
EP4321624A1 (en) | 2024-02-14 |
CA3215029A1 (en) | 2022-10-13 |
CN115197989A (zh) | 2022-10-18 |
AU2022253522A1 (en) | 2023-11-09 |
JP2024513462A (ja) | 2024-03-25 |
US20240192197A1 (en) | 2024-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yue et al. | SLFN2 protection of tRNAs from stress-induced cleavage is essential for T cell–mediated immunity | |
Ye et al. | ATP binding by monarch-1/NLRP12 is critical for its inhibitory function | |
US6242183B1 (en) | Interaction trap systems for detecting protein interactions | |
US20120270273A1 (en) | Transcription activator-like effectors | |
US8481491B2 (en) | Scaffold polypeptides for heterologous peptide display | |
US20080311618A1 (en) | Expression System, Components Thereof and Methods of Use | |
WO2002064790A2 (en) | Jfy1 protein induces rapid apoptosis | |
JP2001505783A (ja) | 分泌ヒトタンパク質 | |
US7919233B2 (en) | Motif of the beclin protein which interacts with anti-apoptotic members of the Bcl-2 protein family, and uses | |
US20150105274A1 (en) | Methods for the Characterisation of Interaction Sites on Target Proteins | |
HRP20050461A2 (en) | Soluble notch-based substrates for gamma secretase and methods and compositions for using same | |
US20170016004A1 (en) | DDX5 AND ASSOCIATED NON-CODING RNAs AND MODULATION OF TH17 EFFECTOR FUNCTION | |
WO2022214023A1 (zh) | 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 | |
EP2190989B1 (en) | Method for manufacturing a modified peptide | |
US7052843B2 (en) | Transcription-based assay for identification of post-translational modification and its application in proteomics | |
Hart et al. | Analysis of the NF-κB p50 dimer interface by diversity screening | |
KR101924896B1 (ko) | 피브로넥틴 edb을 골격으로 한 비항체 단백질 스캐폴드 라이브러리 및 그의 용도 | |
WO2001004300A1 (fr) | Facteur associe a l'apoptose | |
Hagen et al. | Characterization and inhibition of AF10‐mediated interaction | |
US20050191628A1 (en) | Antibiotics based upon bacteriophage lysis proteins | |
KR20060123382A (ko) | 징크 핑거 단백질을 이용한 원핵세포의 유전자 발현 조절 | |
KR20020047289A (ko) | 인간 타이로신키나제 에이치씨케이에 결합하는 인간단백질 및 그것을 코드하는 유전자 | |
WO2015133611A1 (ja) | 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体 | |
CN103124904A (zh) | 食蟹猴ccl17 | |
Wongthida et al. | Analysis of the interaction between human kidney anion exchanger 1 and kanadaptin using yeast two-hybrid systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22784089 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023561631 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18554490 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3215029 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022253522 Country of ref document: AU Ref document number: 2022253522 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20237038520 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237038520 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022253522 Country of ref document: AU Date of ref document: 20220407 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022784089 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022784089 Country of ref document: EP Effective date: 20231109 |